Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Recruiting N/A Interventional Study
Bladder Cancer Urothelial Carcinoma (UC) Oligometastasis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
44 (estimated)
Sponsor
Istituto Clinico Humanitas · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options available. At the moment, standard treatment mainly includes systemic therapies, such as chemotherapy and immunotherapy (immune checkpoint inhibitors). These treatments act on…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * WHO performance status ≤ 2 * Pathological proven urothelial carcinoma * Stage IV disease at imaging * Maximum of 3 extracranial metastases * Indication to receive I or II line of standard systemic therapy * Adequate liver function * Adequate bone marrow funct…
Contacts

Marta Scorsetti, MD, Radiation oncologist

+39 0282248524

marta.scorsetti@hunimed.eu

CONTACT

Ciro Franzese, MD, Radiation oncologist

+39 0282247454

ciro.franzese@hunimed.eu

CONTACT